Postherpetic Neuralgia (PHN) Market Report 2026

The postherpetic neuralgia (phn) market size has grown strongly in recent years. It will grow from $0.77 billion in 2025 to $0.82 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing incidence of herpes zoster infections, limited treatment options for neuropathic pain, reliance on opioid-based pain management, growing elderly population, gradual expansion of hospital pain management services.

The postherpetic neuralgia (phn) market size is expected to see strong growth in the next few years. It will grow to $1.06 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to development of targeted neuropathic pain therapies, rising adoption of biologic and branded drugs, growth of online pharmacy distribution channels, increasing focus on patient-centric pain management, expansion of outpatient and ambulatory care facilities. Major trends in the forecast period include rising prevalence of shingles in aging population, increasing adoption of non-opioid pain management therapies, growing use of transdermal and topical pain relief solutions, higher demand for long-term chronic pain management, improved awareness and early diagnosis of phn.

The rising prevalence of chronic pain conditions is anticipated to drive the growth of the postherpetic neuralgia (PHN) market in the coming years. Chronic pain is defined as persistent or recurring pain that lasts for more than three months, often extending beyond the normal healing period of an illness or injury and negatively impacting an individual’s daily activities and quality of life. The increasing occurrence of chronic pain conditions is largely attributed to an aging population, as older adults are more susceptible to degenerative disorders such as arthritis and neuropathy that result in long-term pain. Postherpetic neuralgia plays an important role in chronic pain research by offering a well-defined model for studying nerve-related pain mechanisms and assessing long-term therapeutic approaches. For instance, in January 2024, according to a report published by the Office for Health Improvement and Disparities, a UK-based government department, approximately 18.4% of individuals aged 16 years and above reported having a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Therefore, the growing prevalence of chronic pain conditions is fueling the growth of the postherpetic neuralgia (PHN) market.

Major companies operating in the postherpetic neuralgia (PHN) market are emphasizing the pursuit of regulatory approvals to broaden their product portfolios, strengthen competitive positioning, and address the substantial unmet need for more effective and better-tolerated treatments. Regulatory approvals are formal authorizations issued by government health authorities that permit a drug or therapy to be marketed and used for a specific medical indication. For example, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, received final approval from the United States Food and Drug Administration to manufacture and market once-daily generic gabapentin tablets in 300 mg and 600 mg strengths for the treatment of postherpetic neuralgia (PHN). Gabapentin tablets are used to manage PHN, a form of neuropathic pain caused by nerve damage following reactivation of the varicella-zoster virus. For PHN management, dosing typically begins at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with gradual titration up to a maximum daily dose of 1800 mg (600 mg three times daily) based on patient response.

In September 2023, Adalvo Limited, a Malta-based pharmaceutical company primarily focused on providing services to other companies, partnered with Lotus Pharmaceutical Co. Ltd. to introduce gabapentin extended-release (ER) tablets in South Korea. This partnership is intended to improve patient access to effective and innovative therapies by launching gabapentin ER in the South Korean market, reinforcing their presence in the neurology segment, and expanding their portfolios with high-value pharmaceutical offerings. Lotus Pharmaceutical Co., Ltd. is a Taiwan-based pharmaceutical company that manufactures treatments for postherpetic neuralgia (PHN).

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the postherpetic neuralgia (phn) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the postherpetic neuralgia market by increasing costs for imported pharmaceutical raw materials and finished drug formulations, impacting pricing and supply consistency. Drug and patch segments are most affected, particularly in regions such as Asia-Pacific and Latin America that rely heavily on cross-border pharmaceutical trade. These tariffs have led to higher treatment costs and slower penetration in cost-sensitive markets. However, they have also encouraged local drug manufacturing, generic drug production, and regional supply chain strengthening to improve market resilience.

The postherpetic neuralgia (phn) market research report is one of a series of new reports that provides postherpetic neuralgia (phn) market statistics, including postherpetic neuralgia (phn) industry global market size, regional shares, competitors with a postherpetic neuralgia (phn) market share, detailed postherpetic neuralgia (phn) market segments, market trends and opportunities, and any further data you may need to thrive in the postherpetic neuralgia (phn) industry. This postherpetic neuralgia (phn) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Postherpetic neuralgia (PHN) is a long-term nerve pain disorder that develops as a complication after an episode of herpes zoster (shingles). It is marked by ongoing, often intense pain in the area where the shingles rash previously occurred, persisting for months or even years after the rash has resolved. Postherpetic neuralgia (PHN) arises from nerve damage caused by reactivation of the varicella-zoster virus and represents the most common complication of shingles, particularly among older adults.

The main types of postherpetic neuralgia (PHN) treatments include patches, drugs, and opioids. Patches are transdermal drug delivery systems applied directly to the skin to allow controlled release of medication into the bloodstream. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by end users such as hospitals, clinics, ambulatory surgical centers, and other healthcare settings.

The postherpetic neuralgia (PHN) market includes revenues earned by entities by providing services such as medical consultation, pain management services, topical treatment application, physical therapy and nerve block or injections. The market value includes the value of related goods sold by the service provider or included within the service offering. The postherpetic neuralgia (PHN) market consists of sales of anticonvulsants, amitriptyline, tramadol, oxycodone, and nortriptyline. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.